|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0167 - 0.0190|
|52 Week Range||0.0025 - 0.1169|
|Beta (3Y Monthly)||1.59|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (ATT.CN) (ATTBF) announces the filing of its annual financial statements for the year ended September 30, 2018 and is pleased to provide the following comprehensive update on recent developments related to Abattis since the trading of the Company’s common shares (each, a “Share”) was halted on the Canadian Securities Exchange (“CSE”) on February 4, 2019. After a long process, the Company has finally filed its annual financial statements, the related management discussion and analysis and the certification of the annual filings for the year ended September 30, 2018 (the “Annual Filings”).
The allure of investing in penny stocks can be quite strong. Every investor has dreams of putting a few thousand dollars in a penny stock and becoming a millionaire when it goes to $100 per share.But you need to be careful. Things aren't always as they seem. Just because it is a penny stock, it isn't necessarily cheap. Companies are typically valued by taking the assets and subtracting the liabilities. Assets consist of things such as cash, property, and inventories. Liabilities consist of things such as debt and loans, salaries, and taxes. These values are easily found on the company's balance sheet.You can also look at the Total Debt to Total Assets ratio. If it is greater than 1, consider it a major red flag. This means liabilities exceed assets.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe following 7 marijuana stocks all have terrible valuations. In other words, their liabilities are greater than their assets. If you are considering investing in penny stocks, this is something that I believe you should take a look at. Does it make sense to invest your money in companies that are essentially bankrupt? * The 7 Top Small-Cap Stocks Of 2019 I'm not saying that you can't make money investing in them. But you don't need to be Warren Buffet to understand that companies that have value and make money will outperform companies with negative valuations that lose money. Penny Stocks: Players Network (PNTV)Players Network (OTCMKTS:PNTV) is involved in the creation of digital networks and broadband distribution. It also grows and processes medical marijuana. And no, I'm not exactly sure how these two seemingly very different businesses are related.Maybe this strange mix is why this company has been such a loser. Last year it lost over $1 million. According to the balance sheet, the total assets of the company are around $1.2 million and the total liabilities are $11.5 million. That means this company has value of -$10.6 million. Despite this, it has a market capitalization of $17 million. Indoor Harvest (INQD)Indoor Harvest Corp (OTCMKTS:INQD) designs and builds fixtures and equipment for the indoor farming industry.This seems like a great industry to be in, but unfortunately things aren't working out so well for INQD. The company's market cap is less than $1 million. This isn't surprising considering that that it only has $200,000 in assets and $2.6 million of liabilities giving it a total value of negative $2.3 million. * The Top 8 Tech Stocks of 2019 (So Far) Last year it posted a loss of $3.3 million and in 2017 the reported loss was $4.4 million. Abattis Bioceuticals (ATTBF)Abattis Bioceuticals (OTCMKTS:ATTBF) is an agricultural and biotechnology company. It invests in technologies and biotechnology services for the legal cannabis industry in Canada.Despite how cool this business description sounds, this company losses a lot of money.Like most of these little penny stock companies, information on ATTBF was hard to find but I think they have lost more than $20 million between 2014 and 2017, an average of $5 million annually. The most recent reported assets were $1.2 million with liabilities of $440,000. This gives it a valuation of about $700,000. It is typically not a good thing when a company post losses that are more than 5 times its valuation. Blue Line Protection Group (BLPG)Blue Line Protection Group (OTCMKTS:BLPG) provides protection, transportation, banking and training services for the legal cannabis industry. This is a fancy way of saying that they are in the security business.Unfortunately for Blue Line they may not need protection for themselves because they probably don't have anything worth stealing. BLPG lost $1.25 million last year. In the prior four years, it lost a total of about $9 million. * 7 Stocks to Buy for the Same Price as Beyond Meat The assets are just $700,000 while the liabilities are $4.2 million. This gives it a total valuation of negative $3.5 million. GreenGro Technologies (GRNH)GreenGro Technologies (OTCMKTS:GRNH) is involved in the sale of greenhouse systems. The company also sells hydroponic supplies at its retail store in Anaheim, California. They sell pretty much anything you could need if you want to build a greenhouse or an indoor growing system.Considering the rapid growth of the cannabis markets, it is reasonable to believe that this would be a great business to be in. Unfortunately for GreenGro, this has not been the case. Last year it lost $3.7 million. In 2017 the loss was $8 million. With assets of $4.6 million and liabilities of $6.6 million, the value is negative $2 million. Rocky Mountain High Brands (RMHB)Rocky Mountain High Brands (OTCMKTS:RMHB) is a lifestyle brand management company. Their products include cannabidiol and hemp-infused products such as spring water and protein drinks. This is and old company with origins going back to 1968. It seems like in all that time they haven't learned how to make consistent profits. Last year the company lost $3.4 million and in 2017 losses were $9.3 million. * 10 Best S&P 500 Stocks to Buy For the Rest of 2019 With assets of $1.4 million and liabilities of $2.1 million, the valuation is about negative $500,000. Sugarmade (SGMD)Sugarmade (OTCMKTS:SGMD) is a distributor of paper products. The company recently announced plans to enter the hemp extraction technologies and equipment market.SGMD has unfortunately not been too sweet to its shareholders. This company hasn't made money in years and the trend seems to be getting worse. In 2016 it lost $2.5 million and it 2017 the loss was $4.7 million. Last years loss of $6.3 million was even worse. It is no surprise that SGMD has a negative valuation. With assets of $2.2 million and liabilities of $12.4 million, the valuation is negative $10.2 million.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 7 Top Small-Cap Stocks Of 2019 * Critical Levels to Watch in 7 Marijuana Stocks * 5 Smaller Cloud Stocks That Have Plenty of Potential Compare Brokers The post 7 Penny Marijuana Stocks That Are NOT Cheap Stocks appeared first on InvestorPlace.
Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce that, further to its news release dated April 2nd, 2019, the Company’s wholly-owned subsidiary, 1185277 B.C. Ltd. (the “Acquisition Subsidiary”) has successfully closed the acquisition (the “Acquisition”) of Pro Natura BV (“Pro Natura”). Abattis is also pleased to announce that it will be relaunching its Company Newsletter (the “Newsletter”), which has been designed to complement the Company’s continuous disclosure, and provide cannabis industry highlights as they pertain to the Company.
VANCOUVER, British Columbia, April 2, 2019 /PRNewswire/ -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce that its wholly-owned subsidiary, 1185277 B.C. Ltd. (the "Acquisition Subsidiary"), has entered into a share purchase agreement (the "Agreement") to acquire (the "Acquisition") Pro Natura BV ("Pro Natura"), a privately held nutraceutical company based in Oisterwijk, Netherlands. Pro Natura has over 30 years of operations and sales experience in Europe, with over 100 products that have been marketed to both long-term repeat customers and new large groups of distributors. Pro Natura has been supported by a seasoned management team that still includes its original founder and has historically boasted €10M+ in per annum sales.
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2019) - Abattis Bioceuticals Corp (CSE: ATT) (OTC Pink: ATTBF) (the "Company" or "Abattis") announces that, effective February 20, 2019 and March 6, 2019, both Wolfgang Richter and James Irving have respectively resigned as directors of the Company.The Company thanks both Mr. Richter and Mr. Irving for their service and wishes each all the best in their future endeavors.About Abattis Bioceuticals Corp.Abattis is positioned to be ...
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) provides the following update on the Company’s recent trading halt and upcoming conference call with Company management that was previously set for March 1, 2019. Further to the Company’s news release dated February 18, 2019, trading of the Company’s common shares continues to be halted on the Canadian Securities Exchange until the Company files its financial statements for the year ended September 30, 2018 (the “Financials”).
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to provide the following update on the Company’s recent trading halt and upcoming conference call with Company management set for March 1, 2019. On February 4, 2019, the trading of the Company’s common shares was halted due to the Company’s failure to file its year-end financial statements within the 90 day filing deadline required under National Instrument 51-102 – Continuous Disclosure Requirements. The Company is still undergoing its year-end financial statement audit and believes it will have them filed in the coming week.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that the temporary order from the British Columbia Securities Commission (“BCSC”), issued on November 26, 2018 (the “Order”), has not been extended against Abattis. “Abattis is very happy with the BCSC’s decision to remove the Company from the Order such that Abattis can continue to focus its efforts on revenue generation and building shareholder value” stated Rob Abenante, President and CEO of Abattis.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that, further to its new release dated December 7, 2018, the Company has entered into a definitive share exchange agreement (the “Agreement”) with 1157016 B.C. Ltd., dba NutriVida, a private arm’s length company incorporated in the Province of British Columbia (“NutriVida”), pursuant to which the Company will acquire 100% of the issued and outstanding common shares of NutriVida (the “Acquisition”). In consideration for the Acquisition, and on closing thereof, the Company will issue an aggregate of 58,823,529 common shares (each, a “Share”) in the capital of Abattis, pro rata, to the NutriVida shareholders at a deemed price of $0.085 per Share and make a cash payment of $250,000 as provided in the Agreement.
Abattis Bioceuticals Corp (the “Company" or "Abattis") (CSE:ATT) (ATTBF) is pleased to announce the launch of its new website and provide an operational update. Abattis has recently unveiled its new marketing and branding materials, developed in conjunction with media company Canada One Communications Inc. (“Canada One”). Marketing materials include an updated website, corporate presentation and conference materials all highlighting Abattis’ new brand imagery (“new marketing materials”).
VANCOUVER, British Columbia, Dec. 18, 2018 /PRNewswire/ -- Abattis Bioceuticals Corp (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce its first proprietary product, Comfort, which has been produced through wholly owned subsidiary Vergence Naturals ("Vergence"). Abattis has teamed up with respected naturopathic doctor and nutraceuticals product developer Dr. Brazos Minshew to launch Comfort, a breakthrough nutraceutical combining traditional herbal remedies to safely and effectively address occasional pain. Released on Cyber Monday and set for introduction into the US and Canada in December 2018, the Comfort product is 100% owned by Vergence, and will be marketed under the newly-formed health and wellness brand.
Vancouver, British Columbia--(Newsfile Corp. - December 14, 2018) - CEO & President of Abattis Bioceuticals Corp., Robert Abenante, speaks on the medical marijuana company's many facets including: a vape line, extraction and laboratory services.If you cannot view the video above, please visit:https://www.b-tv.com/abattis-bioceuticals-ceo-clip-90sec/Abattis Bioceuticals Corp. is being featured on BNN Bloomberg on Dec. 15 - Dec. 16, 2018, throughout the day and evenings.Abattis Bioceuticals (CSE: ATT) (OCTQB: ATTBF)abattis.comAbout CEO Clips:CEO Clips is the largest library ...
Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to provide an update on the recent soft-launch of its cannabinoid-infused nutraceutical Comfort (“Comfort”) through the Company’s wholly-owned subsidiary, Vergence Naturals (“Vergence”), on Cyber-Monday, November 26, 2018. Canada One Communications Inc. (“Canada One”), an Abattis media partner, quotes WorkArea.com in selecting Monday as the best day for e-commerce site sales.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that the Company will be displaying a booth at the O’Cannabiz Conference and Expo taking place at Parq Casino in Vancouver, BC on December 10-11th, 2018 (“O’Cannabiz”). O’Cannabiz will address key cannabis investment themes, emerging opportunities in the developing Canadian market, as well as significant trends and developments in the cannabis industry, from consumers to businesses. The conference will display over 100 global and local cannabis professionals, offering attendees and investors up to date information on what’s next for Canada’s growing cannabis industry.
Abattis Bioceuticals Corp. (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that it has signed a non-binding letter of intent dated December 6, 2018 (the “LOI”) to acquire 100% interest in NutriVida Corp. (“NutriVida”) through an arm’s length transaction, a privately held fertilizer and nutrient company located in Langley, BC. The acquisition of Nurtivida plays directly into the Company’s push to add to its current and future cannabis growth assets, including, but not limited to, its acquisition of Gabriola Green Farms Inc. earlier in 2018. Specifically, the management of NutriVida has been a prominent force in the fertilizer and cultivation industry, with over 35 years of experience and, providing a vast wealth of knowledge and experience in researching, innovating, manufacturing, and selling all-natural, bio-safe, fertilizers and plant nutrients.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) comments on the news release regarding the British Columbia Securities Commission (“BCSC”) Temporary Order dated November 26, 2018. The BCSC issued a temporary order on Monday, November 26, 2018, which centers around share issuances by 11 CSE issuers to a very large group of consultants between February, 2018, and August, 2018. Abattis has been named as 1 of the 11 issuers as they have ongoing consulting agreements with certain members listed in the group of respondents (the “Respondents”) for services ranging from accounting and finance to marketing. Also, certain of the Respondents participated in an Abattis private placement for $2.25M. For these reasons, Abattis has been named as an issuer in this temporary order.
Abattis Bioceuticals Corp (the "Company" or "Abattis") (ATT.CN) (ATTBF) is pleased to announce that the Company has signed a Distribution Agreement (the "Distribution Agreement") with Shefield & Sons Tobacconists Inc. ("Shefield & Sons") to sell the Abattis vaporizer line in all Shefield & Sons stores across Canada. Shefield & Sons has been in business since 1976 and is one of Canada's pre-eminent tobacconist franchisors with locations in major cities across Canada.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce the release of its first proprietary product, Comfort, through the Company’s wholly-owned subsidiary Vergence Naturals (“Vergence”). Comfort, a brand-new proprietary nutraceutical, which contains Alpinia Galangal and Capsicum Annuum, was developed by Abattis’ research scientists to activate the endocannabinoid system (“ECS”) and nourish endorphin release in response to pain. Comfort Extra Strength, the second addition to the Comfort product line, is set to be released to the public in mid-January 2019 and will be enhanced with hemp-based phytocannabinoids, with a specific focus on cannabidiol (CBD).
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce that it has entered into a definitive agreement (the “Agreement”) to acquire 100% of Select Strains Inc. (“Select Strains”). Select Strains has almost two decades of experience within the cannabis space, specifically within the fields of cannabis testing, research, cultivation and optimization of proprietary seeds and strains. With a portfolio of over 140 laboratory-tested craft cannabis strains, Select Strains will allow for the continued differentiation of the Abattis brand, leveraging unique craft strains in an increasingly generic, highly competitive and standardised cannabis market.
Abattis Bioceuticals Corp (the “Company” or “Abattis”) (CSE:ATT) (ATTBF) is pleased to announce the appointment of Ingredient Identity LLC (“Ingredient Identity”), a Canadian and US regulatory and compliance agency, to assist the Company’s wholly-owned subsidiary, Vergence Naturals Ltd. (“Vergence Naturals”), with their ongoing Canadian and US regulatory compliance program. “Regulatory compliance is a cornerstone objective for Vergence Naturals, or any nutraceutical business,” stated Rob Abenante, President and CEO of Vergence Naturals.
CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering the launch of Abattis Bioceuticals Corp.'s (ATT.CN) (ATTBF) latest product innovation. “Comfort”, a nutraceutical designed to alleviate chronic pain and inflammation, is the first in line of a dozen new products the company expects to launch over 36 months. According to a recent Institute of Medicine Report: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, stated, “Acute or chronic pain is a significant public health problem that costs society at least $560-$635 billion annually in North America alone.